Eloxx Pharmaceuticals 5/19/2026 Earnings Report

Eloxx Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$5.07
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Eloxx Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Eloxx Pharmaceuticals Announcement Details

• Date: 5/19/2026
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Eloxx Pharmaceuticals (NASDAQ:ELOX) (NASDAQ: ELOX) is a clinical‐stage biopharmaceutical company focused on developing precision medicines for rare genetic diseases caused by nonsense mutations. Its lead candidate, ELX-02, is a novel small molecule designed to enable ribosomal read-through of premature stop codons and restore production of full-length, functional proteins. The company’s initial therapeutic targets include cystic fibrosis and cystinosis, with ELX-02 advancing through Phase 2 clinical studies in cystic fibrosis and Phase 1/2 trials in cystinosis.

In addition to ELX-02, Eloxx is advancing second-generation read-through compounds in its discovery pipeline to broaden treatment opportunities for patients with other nonsense mutation-driven disorders. The company’s research and development efforts leverage proprietary chemistry to optimize efficacy and safety profiles, and it has established clinical sites across North America and Europe to support multi-regional trials. Eloxx aims to address a high unmet medical need by providing targeted therapies where few or no approved options exist.

Founded in 2016 and incorporated in Delaware, Eloxx Pharmaceuticals is headquartered in Mamaroneck, New York. The company’s management team includes seasoned biotechnology executives with deep expertise in rare disease drug development, clinical operations and regulatory affairs. Eloxx is committed to advancing its pipeline through clinical milestones and to forging strategic collaborations that can accelerate development timelines and expand patient access worldwide.